{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:03:24Z","timestamp":1694639004177},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s11596-010-0346-3","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T17:58:47Z","timestamp":1277229527000},"page":"299-306","source":"Crossref","is-referenced-by-count":1,"title":["Revaluation of clopidogrel: let the data speak for themselves"],"prefix":"10.1007","volume":"30","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fandian","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingmei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoping","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cailian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fagang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuwu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,17]]},"reference":[{"issue":"9038","key":"346_CR1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee.","year":"1996","unstructured":"CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 1996, 348(9038): 1329\u20131339","journal-title":"Lancet"},{"key":"346_CR2","doi-asserted-by":"crossref","unstructured":"Clopidogrel approved on basis of CAPRIE study [editorial]. Am J Health Syst Pharm, 1998,55(3):207","DOI":"10.1093\/ajhp\/55.3.207a"},{"issue":"9","key":"346_CR3","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1161\/01.CIR.100.9.1016","volume":"100","author":"T.J. Ryan","year":"1999","unstructured":"Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC\/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999,100(9): 1016\u20131030","journal-title":"Circulation"},{"issue":"9292","key":"346_CR4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(01)06585-0","volume":"358","author":"C.W. Hamm","year":"2001","unstructured":"Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet, 2001,358(9292):1533\u20131538","journal-title":"Lancet"},{"issue":"3","key":"346_CR5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/1568016054368188","volume":"3","author":"A.S. Manolis","year":"2005","unstructured":"Manolis AS, Tzeis S, Andrikopoulos G, et al. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents, 2005,3(3): 203\u2013219","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"issue":"9","key":"346_CR6","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ehj.2004.03.006","volume":"25","author":"P. Eriksson","year":"2004","unstructured":"Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the \u201cEmperor\u2019s New Clothes\u201d revisited. Eur Heart J, 2004,25(9): 720\u2013722","journal-title":"Eur Heart J"},{"issue":"1","key":"346_CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/WCO.0b013e328013dbc8","volume":"20","author":"G. Howard","year":"2007","unstructured":"Howard G, McClure LA, Krakauer JW, et al. Stroke and the statistics of the aspirin\/clopidogrel secondary prevention trials. Curr Opin Neurol, 2007, 20(1): 71\u201377","journal-title":"Curr Opin Neurol"},{"key":"346_CR8","unstructured":"Yan H, Xu YY, Zhao NQ. Medical Statistics. Beijing: People\u2019s Medical Publishing House (Chinese), 2005, 252\u2013254"},{"issue":"2","key":"346_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ptsp.2009.03.002","volume":"10","author":"Z. Hudson","year":"2009","unstructured":"Hudson Z. Sample size, power and effect size \u2014 what all researchers need to know. Phys Ther Sport, 2009, 10(2):43\u201344","journal-title":"Phys Ther Sport"},{"issue":"2","key":"346_CR10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF03011261","volume":"43","author":"J. Lerman","year":"1996","unstructured":"Lerman J. Study design in clinical research: sample size estimation and power analysis. Can J Anaesth, 1996, 43(2):184\u2013191","journal-title":"Can J Anaesth"},{"issue":"9","key":"346_CR11","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1007\/s11999-008-0346-9","volume":"466","author":"D.J. Biau","year":"2008","unstructured":"Biau DJ, Kern\u00e9is S, Porcher R. Statistics in brief: the importance of sample size in the planning and interpretation of medical research. Clin Orthop Relat Res, 2008,466(9):2282\u20132288","journal-title":"Clin Orthop Relat Res"},{"issue":"7","key":"346_CR12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators.","year":"2001","unstructured":"The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001,345(7):494\u2013502","journal-title":"N Engl J Med"},{"issue":"9281","key":"346_CR13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"S.R. Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527\u2013533","journal-title":"Lancet"},{"issue":"19","key":"346_CR14","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"S.R. Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA, 2002,288(19):2411\u20132420","journal-title":"JAMA"},{"issue":"12","key":"346_CR15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med, 2005,352(12):1179\u20131189","journal-title":"N Engl J Med"},{"issue":"16","key":"346_CR16","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"D.L. Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 2006,354(16): 1706\u20131717","journal-title":"N Engl J Med"},{"issue":"9431","key":"346_CR17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","volume":"364","author":"H.C. Diener","year":"2004","unstructured":"Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 2004,364(9431): 331\u2013337","journal-title":"Lancet"},{"issue":"6","key":"346_CR18","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/01.CIR.102.6.624","volume":"102","author":"M.E. Bertrand","year":"2000","unstructured":"Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation, 2000,102(6): 624\u2013629","journal-title":"Circulation"},{"issue":"9497","key":"346_CR19","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","volume":"366","author":"Z.M. Chen","year":"2005","unstructured":"Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet, 2005,366(9497):1607\u20131621","journal-title":"Lancet"},{"issue":"9526","key":"346_CR20","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","volume":"367","author":"S. Connolly","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet, 2006,367(9526): 1903\u20131912","journal-title":"Lancet"},{"issue":"20","key":"346_CR21","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"S.D. Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007,357(20):2001\u20132015","journal-title":"N Engl J Med"},{"issue":"18","key":"346_CR22","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1093\/eurheartj\/ehm274","volume":"28","author":"T.H. Wang","year":"2007","unstructured":"Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J, 2007,28(18):2200\u20132207","journal-title":"Eur Heart J"},{"issue":"2","key":"346_CR23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","volume":"30","author":"P.P. Cacoub","year":"2009","unstructured":"Cacoub PP, Bhatt DL, Steg PG, et al. Creager for the CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J, 2009,30(2):192\u2013201","journal-title":"Eur Heart J"},{"key":"346_CR24","first-page":"223","volume-title":"Application of statistical triple-type theory in the design of experiments","author":"L.P. Hu","year":"2006","unstructured":"Hu LP. Application of statistical triple-type theory in the design of experiments. Beijing: People\u2019s Military Medical Press (Chinese), 2006,223\u2013230"},{"key":"346_CR25","first-page":"9","volume-title":"Adequacy of sample size in health studies","author":"S. Lemeshow","year":"1990","unstructured":"Lemeshow S, Hosmer DW, Klar J, et al. Adequacy of sample size in health studies. The World Health Organization and John Wiley and Sons, New York, NY. 1990:9\u201314"},{"key":"346_CR26","first-page":"310","volume-title":"The statisitical analysis by EXCEL and computer experiment","author":"C.H. Yu","year":"2009","unstructured":"Yu CH. The statisitical analysis by EXCEL and computer experiment. Beijing: China Publishing House of Electronics Industry (Chinese), 2009,310\u2013319"},{"key":"346_CR27","first-page":"30","volume-title":"Sample size estimation in clinical studies","author":"S.X. Wu","year":"2008","unstructured":"Wu SX, WANG CX. Sample size estimation in clinical studies. Beijing: People\u2019s Medical Publishing House (Chinese), 2008,30\u201332"},{"key":"346_CR28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1201\/9780203911341","volume-title":"Sample size calculations in clinical research","author":"S.C. Chow","year":"2003","unstructured":"Chow SC, Shao J, Wang HS. Sample size calculations in clinical research. New York: Taylor & Francis, 2003:92"},{"issue":"4","key":"346_CR29","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08998280.2005.11928091","volume":"18","author":"R.I. Myers","year":"2005","unstructured":"Myers RI. The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials. Proc (Bayl Univ Med Cent), 2005,18(4): 331\u2013336","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"346_CR30","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1161\/01.STR.0000110221.54366.49","volume":"35","author":"P.A. Ringleb","year":"2004","unstructured":"Ringleb PA, Bhatt DL, Hirsch AT, et al. Benefit of clopigogrel over aspirin is amplified in patients with a history of ischemic events. Stroke, 2004,35(2):528\u2013532","journal-title":"Stroke"},{"issue":"6","key":"346_CR31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","volume":"90","author":"D.L. Bhatt","year":"2002","unstructured":"Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol, 2002,90(6):625\u2013628","journal-title":"Am J Cardiol"},{"key":"346_CR32","unstructured":"Sanofi-Synth\u00e9labo warned on Plavix [editorial]. Scrip, 2001,2652:13"},{"issue":"6","key":"346_CR33","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jacc.2004.11.051","volume":"45","author":"W.S. Weintraub","year":"2005","unstructured":"Weintraub WS, Mahoney EM, Lamy A, et al. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.J Am Coll Cardiol, 2005,45(6): 838\u2013845","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"346_CR34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jacc.2005.03.073","volume":"46","author":"S.C. Beinart","year":"2005","unstructured":"Beinart SC, Kolm P, Veledar E, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol, 2005, 46(5): 761\u2013769","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"346_CR35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ahj.2005.02.044","volume":"151","author":"E.M. Mahoney","year":"2006","unstructured":"Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J, 2006,151(1):219\u2013227","journal-title":"Am Heart J"},{"issue":"Suppl4","key":"346_CR36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00019053-200422004-00006","volume":"22","author":"W. Weintraub","year":"2004","unstructured":"Weintraub W, J\u00f6nsson B, Bertrand M. The value of clopidogrel in addition to standard therapy in reducing atherothrombotic events. Pharmacoeconomics, 2004, 22(Suppl 4):29\u201341","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"346_CR37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/00019053-200624070-00009","volume":"24","author":"K.A. Lyseng-Williamson","year":"2006","unstructured":"Lyseng-Williamson KA, Plosker GL. Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes. Pharmacoeconomics, 2006,24(7):709\u2013726","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"346_CR38","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jacc.2005.11.025","volume":"47","author":"S.C. Smith Jr","year":"2006","unstructured":"Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (ACC\/AHA\/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol, 2006,47(1):216\u2013235","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"346_CR39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.annemergmed.2008.04.004","volume":"52","author":"C.V. Pollack Jr","year":"2008","unstructured":"Pollack CV Jr, Antman EM, Hollander JE, et al. 2007 focused update to the ACC\/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice. Ann Emerg Med, 2008,52(4): 344\u2013355","journal-title":"Ann Emerg Med"},{"issue":"23","key":"346_CR40","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1093\/eurheartj\/ehn416","volume":"29","author":"F. Werf Van de","year":"2008","unstructured":"Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2008,29(23): 2909\u20132945","journal-title":"Eur Heart J"},{"issue":"7637","key":"346_CR41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bmj.39430.529549.BE","volume":"336","author":"G. Krasopoulos","year":"2008","unstructured":"Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin \u201cresistance\u201d and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ, 2008,336(7637): 195\u2013198","journal-title":"BMJ"},{"issue":"1","key":"346_CR42","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","volume":"140","author":"D.L. Bhatt","year":"2000","unstructured":"Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J, 2000,140(1):67\u201373","journal-title":"CAPRIE investigators. Am Heart J"},{"issue":"8-9","key":"346_CR43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00228-003-0672-5","volume":"59","author":"B. B\u00e9gaud","year":"2003","unstructured":"B\u00e9gaud B, Fourrier A, Moore N, et al. The delusion of reducing sample size. Eur J Clin Pharmacol, 2003, 59(8-9):711\u2013712","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"346_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0899-9007(01)00762-6","volume":"18","author":"G. Fitzmaurice","year":"2002","unstructured":"Fitzmaurice G. Sample size and power: how big is big enough? Nutrition, 2002,18(3):289\u2013290","journal-title":"Nutrition"},{"issue":"5","key":"346_CR45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00268-005-7921-y","volume":"29","author":"U. Guller","year":"2005","unstructured":"Guller U, Oertli D. Sample Size Matters: A Guide for Surgeons. World J Surg, 2005,29(5):601\u2013605","journal-title":"World J Surg"},{"issue":"1","key":"346_CR46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cacc.2007.03.011","volume":"19","author":"M.O. Columb","year":"2008","unstructured":"Columb MO, Stevens A. Power analysis and sample size calculations. Current Anaesthesia & Critical Care, 2008, 19(1):12\u201314","journal-title":"Current Anaesthesia & Critical Care"},{"issue":"2","key":"346_CR47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jchromb.2006.10.002","volume":"847","author":"P. Araujo","year":"2007","unstructured":"Araujo P, Fr\u00f8yland L. Statistical power and analytical quantification. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 847(2):305\u2013308","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"346_CR48","first-page":"52","volume-title":"Adequacy of sample size in health studies","author":"S. Lemeshow","year":"2001","unstructured":"Lemeshow S, Hosmer DW, Klar J, et al. Adequacy of sample size in health studies. Shanghai: Fudan University Press and Shanghai Medcial University Press (Authorized by The World Health Organization) (Chinese), 2001, 52\u201354"},{"key":"346_CR49","first-page":"266","volume-title":"Statistics for Business and Economics(9th Edition)","author":"D.R. Anderson","year":"2008","unstructured":"Anderson DR, Sweeney DJ, Williams TA. Statistics for Business and Economics(9th Edition). Beijing: China Machine Publishing House (Chinese), 2008,266\u2013268"},{"key":"346_CR50","first-page":"369","volume-title":"Statistics for Business and Economics","author":"J.T. McClave","year":"2008","unstructured":"McClave JT, Benson PG, Sinich T. Statistics for Business and Economics (8th Edition). Beijing: China Finacial & Economic Publishing House (Authorized by Pearson Education,Inc.) (Chinese), 2008,369\u2013371","edition":"8th Edition"},{"key":"346_CR51","first-page":"274","volume-title":"Probability Theory & Mathematical Statistics","author":"Z.X. Ye","year":"2008","unstructured":"Ye ZX, Wang RH, Xu XL, et al. Probability Theory & Mathematical Statistics. Beijing: Perking University Press (Chinese), 2008,274\u2013279"},{"key":"346_CR52","first-page":"189","volume-title":"Business Management Statistics","author":"C.L. Huang","year":"2009","unstructured":"Huang CL. Business Management Statistics. Beijing: Tsinghua University Press (Chinese), 2009,189\u2013191"},{"key":"346_CR53","first-page":"194","volume-title":"Statistics","author":"J.P. Jia","year":"2009","unstructured":"Jia JP, He XQ, Jin YJ. Statistics (4th Edition). Beijing: China Renmin University Press (Chinese), 2009,194","edition":"4th Edition"},{"issue":"4","key":"346_CR54","first-page":"235","volume":"1","author":"G.J. Liu","year":"2001","unstructured":"Liu GJ, Hong Q. Application of confidence interval(CI). Chin J Evidence-Based Med (Chinese), 2001,1(4):235\u2013238","journal-title":"Chin J Evidence-Based Med (Chinese)"},{"issue":"3","key":"346_CR55","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa042087","volume":"352","author":"F.K. Chan","year":"2005","unstructured":"Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med, 2005,352(3):238\u2013244","journal-title":"N Engl J Med"},{"issue":"10","key":"346_CR56","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B. Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999,341(10):709\u2013717","journal-title":"N Engl J Med"},{"issue":"12","key":"346_CR57","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2004.03.008","volume":"116","author":"J.M. Gaspoz","year":"2004","unstructured":"Gaspoz JM, de Moerloose P. Aspirin or clopidogrel for secondary prevention of cardiovascular events: is there a winner? Am J Med, 2004,116(12):850\u2013852","journal-title":"Am J Med"},{"issue":"Suppl4","key":"346_CR58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00019053-200422004-00005","volume":"22","author":"I. Durand-Zaleski","year":"2004","unstructured":"Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics, 2004,22(Suppl 4): 19\u201327","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"346_CR59","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1185\/030079908X253762","volume":"24","author":"K. Berger","year":"2008","unstructured":"Berger K, Hessel F, Kreuzer J, et al. Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany. Curr Med Res Opin, 2008,24(1):267\u2013274","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"346_CR60","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7326\/0003-4819-142-4-200502150-00007","volume":"142","author":"M.D. Schleinitz","year":"2005","unstructured":"Schleinitz MD, Heidenreich PA. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann Intern Med, 2005,142(4):251\u2013925","journal-title":"Ann Intern Med"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-010-0346-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11596-010-0346-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11596-010-0346-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T23:52:22Z","timestamp":1635551542000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11596-010-0346-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["346"],"URL":"https:\/\/doi.org\/10.1007\/s11596-010-0346-3","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}